Yonhap Infomax NewsSep 22
Celltrion has obtained Japanese regulatory approval for its Actemra biosimilar Avtozma, targeting key autoimmune indications and aiming to expand its presence in Japan’s pharmaceutical market.
#YonhapInfomax #Celltrion #Avtozma #Biosimilar #JapanApproval #AutoimmuneDiseases #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82759
Celltrion Secures Regulatory Approval for Autoimmune Disease Biosimilar 'Avtozma' in Japan

Celltrion has obtained Japanese regulatory approval for its Actemra biosimilar Avtozma, targeting key autoimmune indications and aiming to expand its presence in Japan’s pharmaceutical market.

Yonhap Infomax